Government-enterprise collaboration: activating a powerful engine for the development of the biopharmaceutical industry

On the afternoon of December 2, 2024, Zheng Quan, Standing Committee Member of the Ji'an Municipal Party Committee, Vice Mayor, and Head of the Municipal Biopharmaceutical Industry Chain, personally led a team of officials from the municipal and district market supervision bureaus and relevant departments, accompanied by Li Minggang, Deputy Secretary-General of the Municipal Government, and Dai Zhimin, Deputy Director of the District Management Committee, to conduct an in-depth field research at the company. Yao Xiaodong, General Manager of the company, warmly welcomed the delegation and provided a comprehensive introduction to the company's strategic blueprint for national biopharmaceutical industry chain layout and its significant progress in research and development.

In his introduction, General Manager Yao Xiaodong pointed out that the company, with its far-sighted strategic vision, is actively deploying the biopharmaceutical industry chain nationwide. From upstream raw material supply to midstream core technology research and development and manufacturing, and downstream product sales and market expansion, a complete and forward-looking system has been established. In terms of R&D progress, the company is currently fully committed to tackling multiple key projects, has overcome multiple technological bottlenecks, and has entered the critical stage of clinical trials, adding new impetus to the development of China's biopharmaceutical industry.

Subsequently, led by General Manager Yao Xiaodong, the research team conducted an on-site investigation of the production line. The research team carefully examined every detail of the production process, gaining a direct and in-depth understanding of the company's efficient, standardized, and refined production and operation, and highly praised and fully affirmed the important role the company plays in the biopharmaceutical industry chain. It was unanimously agreed that with its excellent technological innovation capabilities, rigorous production management system, and extensive market layout, the company has become a shining star in the biopharmaceutical industry field in Ji'an and even nationwide, setting a good example for other companies in the industry and playing a crucial leading and exemplary role in the stability and development of the entire biopharmaceutical industry chain.

When the research team entered the new product R&D laboratory, it was as if they had stepped into a cutting-edge scientific and technological front filled with infinite possibilities. Vice Mayor Zheng Quan inquired in detail about the progress of new product research and development, and conducted in-depth discussions on the innovation, market prospects, and technical difficulties of each product under research. At the same time, they were also very concerned about the difficulties and demands the company faces in its development. General Manager Yao Xiaodong truthfully reflected on some of the challenges the company currently faces in talent introduction and support policies for new drug review and approval. After carefully listening, Vice Mayor Zheng Quan immediately stated that the municipal government regards the company's development as a top priority and attaches great importance to the various problems the company faces. In future work, not only will it continue to closely monitor the company's dynamics, but it will also actively communicate and coordinate with relevant competent departments, spare no effort to solve problems for the company, and work together to build the city's biopharmaceutical industry chain.

This research activity fully demonstrates the Ji'an municipal government's unwavering commitment to and support for the company's biopharmaceutical industry. It paints a grand blueprint full of hope and potential for the vigorous development of the city's biopharmaceutical industry, contributing even more outstanding strength to regional economic growth, improved people's health and well-being, and the overall progress of the national biopharmaceutical industry.